Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
Johnson AP, Wilcox MH.
J Antimicrob Chemother · research support, non-u.s. gov't; review; journal article · DOI 10.1093/jac/dks302 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för fidaxomicin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
22 hitsFidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.
Sclar DA, Robison LM, Oganov AM, Schmidt JM, Bowen KA, Castillo LV.
Clin Drug Investig · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1007/bf03261906Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
Weiss K, Allgren RL, Sellers S.
Clin Infect Dis · comparative study; research-article; review; journal article · DOI 10.1093/cid/cis390Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
Sears P, Crook DW, Louie TJ, Miller MA, Weiss K.
Clin Infect Dis · clinical trial, phase iii; research-article; randomized controlled trial; journal article · DOI 10.1093/cid/cis337Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ.
Clin Infect Dis · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/cis440Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis.
Artsimovitch I, Seddon J, Sears P.
Clin Infect Dis · research-article; journal article · DOI 10.1093/cid/cis358Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ, Cannon K, Byrne B, Emery J, Ward L, Eyben M, Krulicki W.
Clin Infect Dis · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/cis338Antimicrobial activities of fidaxomicin.
Goldstein EJ, Babakhani F, Citron DM.
Clin Infect Dis · research-article; journal article · DOI 10.1093/cid/cis339Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL.
Clin Infect Dis · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1093/cid/cis462Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE, Study 003/004 Teams.
Clin Infect Dis · meta-analysis; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1093/cid/cis499Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Crawford T, Huesgen E, Danziger L.
Am J Health Syst Pharm · comparative study; review; journal article · DOI 10.2146/ajhp110371Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies.
Chen LF, Anderson DJ.
Future Microbiol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.2217/fmb.12.44Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN.
Clin Infect Dis · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/cis430Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Liao CH, Ko WC, Lu JJ, Hsueh PR.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1128/aac.00191-12Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group.
Lancet Infect Dis · clinical trial, phase iii; comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s1473-3099(11)70374-7Fidaxomicin for the treatment of Clostridium difficile infections.
Whitman CB, Czosnowski QA.
Ann Pharmacother · review; journal article · DOI 10.1345/aph.1q481Fidaxomicin, a new treatment for Clostridium difficile infections.
Epstein L, Golan Y.
Drugs Today (Barc) · review; journal article; research support, n.i.h., extramural · DOI 10.1358/dot.2012.48.2.1746740Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ.
Antimicrob Agents Chemother · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.06305-11Clostridium difficile infection in older adults: a review and update on its management.
Kee VR.
Am J Geriatr Pharmacother · review; journal article · DOI 10.1016/j.amjopharm.2011.12.004Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW, Matthews SJ.
Clin Ther · review; journal article · DOI 10.1016/j.clinthera.2011.12.003Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection.
Venugopal AA, Johnson S.
Clin Infect Dis · review; journal article · DOI 10.1093/cid/cir830Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101.
Författaruppgift saknas
Drugs R D · research-article; review; journal article · DOI 10.2165/11537730-000000000-00000